Global Hereditary Angioedema (HAE) Market: Overview
Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal.
For the treatment of hereditary angioedema, currently there are no medications available; hence, the medicines that are prescribed to patients help in management of the disease symptoms. On the basis of the treatment of hereditary angioedema, the market is segmented into different classes of drugs which are used to manage the symptoms of disease which are as follows:
- C1-inhibitors (Cinryze, Berinert, ruconest)
- Ecallantide (Kalbitor)
- Icatibant (Firazyr)
C1-inhibitors are considered as the best treatment method for hereditary angioedema, and berinert among them captures the major share of market. This class of the drugs helps in managing the acute attacks of HAE. Among all the drugs, Berinert was the first and only therapy that received approval in Europe in 2008. However, in between 2008 and 2011, three drugs got approval in Europe which include cinryze, firazyr and ruconest while four drugs were approved by Food and Drug Association (FDA) in the U.S. which included berinert, cinryze, firazyr and kalbitor. In addition to this, prophylactic treatment is also recommended by the doctors for preventing the hereditary angioedema attacks. For prophylactic treatment, cinryze and danazol are the two drugs which are approved by the FDA. In spite of their high cost, these drugs are growing at faster pace and are expected to boost the hereditary angioedema market in forecast period.
Global Hereditary Angioedema (HAE) Market: Key Segments
Hereditary angioedema market can be segmented on the basis of the types of hereditary angioedema, diagnosis methods and treatment methods. On the basis of types of HAE, hereditary angioedema market is classified into three types namely:
- Type I HAE
- Type II HAE
- Type III HAE
Type I HAE captures the major share of the hereditary angioedema market followed by type II HAE. Type I and Type II HAE occurs due to mutation in SERPING1 gene. This gene is responsible for making C1 protein, small protein that assists human immune system. However, type III HAE is associated with Factor XII gene which assists the blood clotting process. Type III HAE is the hereditary angioedema affecting primarily women, and it becomes worse in case of pregnancy and use of birth control pills. On the basis of the diagnosis method the hereditary angioedema market is differentiated into two types which include:
- Blood tests
- Abdominal radiography
- Chest radiography
- Abdominal ultrasonography
Blood tests capture the major share of the hereditary angioedema diagnosis market. The factors which are analyzed for confirmation of disease include C1 esterase inhibitor level, C4 and C2 levels and C1q levels in the blood sample. Abdominal radiography or abdominal ultrasonography is performed during the attacks of gastrointestinal edema while chest radiography is performed to confirm pleural effusions.
Global Hereditary Angioedema (HAE) Market: Trends
Extensive research and development associated with the treatment methods for HAE is the major factor which is driving the hereditary angioedema market. As for instance, one of the major market players BioCryst Pharmaceuticals, Inc. has successfully completed the phase II clinical trials of BCX 4161 and it is expected that this drug will provide efficient results in the forecast period resulting in the growth of the market. However, high cost associated with the available treatments and less awareness about the disease condition are the two major factors which are restraining the hereditary angioedema market. Geographically, HAE market is classified into four segments which include North America, Europe, Asia-Pacific and Rest of the World.
Global Hereditary Angioedema (HAE) Market: Companies Mentioned in the report
Other major market players of hereditary angioedema market include Isis Pharmaceuticals, Inc., Pharming Group N.V., Dyax Corporation, ViroPharma, Inc., CSL Limited and iBio, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.